Start Date
End Date
Event Speciality
Event Cost:
1200
$
Event Capacity
20
For registration/tickets purchase:
https://www.complianceonline.com/fdas-new-import-program-concerning-international-consequences-seminar-training-80133SEM-prdsm?channel=medicalevents
Event Sponsors
Pharmaceutical-Tech
Notable Speakers
Casper (Cap) Uldriks
Session Start Date
Session End Date
Exhibits start date
Exhibits end date
Brief Description

Preparing for FDA's New Import/Export Trauma in 2020 2020 Burlingame United States

Abstract Submission Deadline
Abstract guidelines

Preparing for FDA's New Import/Export Trauma in 2020 2020 Burlingame United States

Learning Objectives:

  • FDA’s new cost-saving import programs
  • Understand how U.S.

Preparing for FDA's New Import/Export Trauma in 2020 Burlingame United States

The FDA continues to change its import program to better manage new problems and to use new procedures to make the whole process easier. The FDA and U.S. Customs and Border Protection (CBP) are relying more and more on computer programs to expedite the import process. When and how you use these programs can make a big difference in the net profit derived from even a single shipment. The new Voluntary Qualified Importer Program (VQIP) is one such example. Another example is CBP’s and FDA’s implementation of the Automated Commercial Environment (ACE) program became mandatory for importers in 2016. If you fail to correctly use new import procedures and programs, you will be operating under an expensive disadvantage.

Topic Background:

FDA’s import and export program is complex and keeps changing. The FDA’s and the U.S. Custom’s new import and enforcement program operates with a streamlined computer system and can leave firms at a loss to understand the short term and long term effects of a detained shipment. The law now requires foreign firms to register and submit specific information to enter U.S. commerce.

Foreign establishments are subject to FDA inspections and quality testing. Failing either FDA activity typically prevents a foreign firm’s product from entering U.S. commerce. If product is detained, resolving the problem with FDA is time consuming, expensive and uncertain. Without an adequate or informed approach to your import program, the specialized federal government process and roadblocks can seem impossible to overcome. To compound the problems, working with foreign establishments presents inherent difficulties based on cultural differences business practices and language barriers.

Other foreign and domestic and legal requirements intersect with FDA’s import and export program, some for the better, some not. For example, not all foreign firms are treated the same under the FDA’s law. A clear example is the FDA’s uses of automatic detention based on the country of origin, type of product or an establishment’s history. With the growing use of off-shore operations, managing imported products can and does present obvious and hidden

Contact Organizer

Please login/register to communicate with the organizers of this event.

Country: United States     City: Burlingame California
(1+) 206-575-7771
World Medical Events Company
12922 SE 299th Street, Auburn WA 98092 USA